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Abstract The Berlin Fat Mouse Inbred (BFMI) line har-
bors a major recessive gene defect on chromosome 3
(jobes1) leading to juvenile obesity and metabolic syn-
drome. The present study aimed at the identification of
metabolites that might be linked to recessively acting genes
in the obesity locus. Firstly, serum metabolites were ana-
lyzed between obese BFMI and lean B6 and BFMI 9 B6 F1
mice to identify metabolites that are different. In a second
step, a metabolite–protein network analysis was performed
linking metabolites typical for BFMI mice with genes of the
jobes1 region. The levels of 22 diacyl-phosphatidylcholines
(PC aa), two lyso-PC and three carnitines were found to be
significantly lower in obese mice compared with lean mice,
while serine, glycine, arginine and hydroxysphingomyelin
were higher for the same comparison. The network analysis
identified PC aa C42:1 as functionally linked with the genes
Ccna2 and Trpc3 via the enzymes choline kinase alpha and
phospholipase A2 group 1B (PLA2G1B), respectively.
Gene expression analysis revealed elevated Ccna2 expres-
sion in adipose tissue of BFMI mice. Furthermore, unique
mutations were found in the Ccna2 promoter of BFMI mice
which are located in binding sites for transcription factors or
micro RNAs and could cause differential Ccna2 mRNA
levels between BFMI and B6 mice. Increased expression of
Ccna2 was consistent with higher mitotic activity of adi-
pose tissue in BFMI mice. Therefore, we suggest a higher
demand for PC necessary for adipose tissue growth and
remodeling. This study highlights the relationship between
metabolite profiles and the underlying genetics of obesity in
the BFMI line.
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1 Introduction
Obesity results from a sedentary lifestyle with malnutrition
and low physical activity and is a risk factor for the
development of the metabolic syndrome. The increasing
number of obese humans correlates with the incidence of
diabetes mellitus and coronary heart diseases (Kopelman
2000). Therefore, biomarkers for the diagnosis of meta-
bolic dysfunctions would be desirable to initiate prevention
or therapeutic programs early in life. A new approach for
biomarker identification is the metabolomics (Shaham
et al. 2008; Shah et al. 2010; Wang-Sattler et al. 2012).
As an emerging technology, metabolic profiling com-
prises the identification and quantification of molecules
with a small molecular weight in biological fluids (Nich-
olson et al. 1999). Metabolites are influenced by factors
such as age, sex and diet but also diseases such as diabetes
(Williams et al. 2005; Lutz et al. 2006; Kim et al. 2011;
Mittelstrass et al. 2011; Yu et al. 2012; Wang-Sattler et al.
2012). In mice, studies suggested metabolic profiling to be
a surrogate for detecting dietary-induced insulin resistance
or diabetes (Shearer et al. 2008). For example, previously,
N-acetyl-L-leucine was identified as a potential biomarker
for diabetes (Tsutsui et al. 2011). In humans, metabolic
profiling was used to find alteration of plasma lipids to
differentiate between healthy and diabetic subjects (Wang
et al. 2005). In addition, three lyso-phosphatidylcholines
(lysoPC) were reported as potential biomarkers for over-
weight in humans (Kim et al. 2010). Some studies asso-
ciated metabolomics and transcriptomics to uncover the
relationship between metabolites and gene expressions in
different species (Askenazi et al. 2003; Bono et al. 2003;
Urbanczyk-Wochniak et al. 2003; Hirai et al. 2004). Albeit
several epidemiological studies and genome-wide associ-
ation studies have repeatedly demonstrated that the
development of obesity also depends on the genetic pre-
dispositions (Stunkard et al. 1986; Allison et al. 1996;
Barsh et al. 2000; Speliotes et al. 2010), most metabolomic
studies have not considered the underlying genetics.
Genetically well-defined mouse inbred models for obesity
can contribute to identify metabolic markers for obesity and
to link them to genetic determinants. We examined the
Berlin Fat Mouse Inbred (BFMI) line which develops juve-
nile obesity (Wagener et al. 2006). Young BFMI mice are
hyperphagic and develop the metabolic syndrome with
impaired insulin sensitivity which was more pronounced on
a high fat diet (HFD), and high serum triglyceride levels
(Meyer et al. 2009; Hantschel et al. 2011). A region on
chromosome 3, named jObes1, showed strong recessive
gene effects on the obesity phenotype in a linkage study in
the cross BFMI 9 C57BL/6NCrl (B6) (Neuschl et al. 2010).
The aim of the present study was the identification of
candidate genes which are responsible for metabolite
profiles associated with obesity in the obese BFMI mouse
model. We have analyzed metabolites in BFMI mice in
comparison with lean B6 mice and the F1 offspring of the
cross BFMI 9 B6 which are lean as well due to the
recessive jobes1 effect. A metabolite–protein network
analysis was performed connecting significantly differen-
tially regulated metabolites with candidate genes for
obesity of the jObes1 region on mouse chromosome 3.
2 Materials and methods
2.1 Animals and diets
In this study we used the lines BFMI860/Hber (BFMI) and
C57BL/6NCrl (B6) and F1 individuals generated by
crossing BFMI and B6 mice. A detailed description of the
breeding history of the BFMI line is outlined in Wagener
et al. (2006). In brief, the BFMI line was generated from
the outbred population Berlin Fat Mouse (BFM). Founders
of BFM mice were originally purchased from pet shops and
subsequently selected first for low protein content, second
for low body mass and high fat content and then for high
fatness for 58 generations before inbreeding. As no control
line of the selection experiment exists, we used B6 mice of
the substrain C57BL6/NCrl as lean controls (Charles River
Laboratories, Sulzfeld, Germany) which were also used to
map genetic loci affecting obesity in the cross BFMI 9 B6
(Neuschl et al. 2010). Mice were reproduced in our animal
facility at the Humboldt-Universita¨t zu Berlin. Mice were
kept at room temperature (22–24 C) with a light dark
cycle of 12 h. After weaning at the age of 3 weeks, 4–5
mice of each line (BFMI, B6 and F1) and of each sex were
randomly chosen and placed on either a standard mainte-
nance diet (SMD) containing 12.8 MJ/kg metabolizable
energy with 9 % of its energy from fat, 33 % from protein
content and 58 % from carbohydrates (V1534-000 ssniff
R/M-H, ssniff Spezialdia¨ten GmbH, Soest, Germany) or a
HFD containing 19.1 MJ/kg metabolizable energy with
45 % of its energy from fat, 24 % from protein content and
31 % from carbohydrates (S8074-E010 ssniff EF R/M,
ssniff Spezialdia¨ten GmbH, Soest, Germany). The standard
diet derived its fat from soy oil, whereas the high-fat diet
derived its fat from coconut oil and suet. The animals had
ad libitum access to diets and water. All animal treatments
were in accordance to the German Animal Welfare Leg-
islation (approval no. G0152/04, T0149/04).
2.2 Body weight, body composition, blood collection
and the measurement of serum parameters
At the age of 10 weeks body weight and body fat mass
were determined by a quantitative magnetic resonance
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analysis using the EchoMRI whole body composition
analyzer (Echo Medical Systems, Houston, Texas, USA)
(Taicher et al. 2003; Tinsley et al. 2004). The recorded fat
mass represented the total fat mass in the body.
After a fasting period of 2 h and anesthesia with iso-
fluran, 10 weeks old mice were sacrificed and reproductive
adipose tissue, liver, brain, pancreas and blood was col-
lected. Serum was recovered by centrifugation for 15 min
at 6009g. Serum and tissues were stored at -80 C until
analysis.
Serum triglycerides were determined using the Fluitest
TG (Analyticon Biotechnologies AG, Lichtenfels, Ger-
many). Serum non-esterifies free fatty acids (NEFAs) were
measured using the NEFA-HR(2) kit (Wako Chemicals
GmbH, Neuss, Germany).
2.3 Measurement of metabolites
For the measurement of metabolites a 10 ll volume of
serum samples was used. The Hamilton Star robotics
(Bonaduz, Switzerland) was used for liquid handling of
samples. A total of 163 metabolite molecules including 41
acylcarnitines, 14 amino acids, one sugar, 92 glycero-
phospholipids and 15 sphingolipids were measured (Table
S1) using the AbsoluteIDQTM p150 Kit following the
manufacturer’s instructions (BIOCRATES Life Sciences
AG, Innsbruck, Austria) on the ion trap mass spectrometry
API 4000 Q TRAP LC/MS/MS System (Applied Biosys-
tems Deutschland GmbH, Darmstadt, Germany). The
AbsoluteIDQTM p150 kit has been described in detail
previously (Illig et al. 2010; Ro¨misch-Margl et al. 2011).
Analytics were calculated in lmol concentrations using the
MetIQ software which was integrated in the Abso-
luteIDQTM kit. To control the quality of metabolites, the
coefficients of variation (CV) were calculated using the
reference samples for each metabolite and 43 metabolites
with CV higher than 0.2 were excluded and 120 metabo-
lites were remained for further analysis (Mittelstrass et al.
2011; Wang-Sattler et al. 2012).
2.4 Statistics
2.4.1 ANOVA of phenotypes and metabolites
Phenotypic data were analyzed by performing the analysis
of variance (ANOVA) to assess the effect of lines using the
SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Multiple pairwise comparisons were Bonferroni-corrected.
Gene expression data analysis was performed using a two
tailed student’s t-test (GraphPad Prism 5 Software, San
Diego, CA/USA). Differences were considered statistically
significant at p \ 0.05.
The remaining 120 out of 163 metabolites were log-
transformed to remove skewness. In a first analysis the
effects of sex, diet, and line on metabolite levels of BFMI,
B6, and F1 mice were assessed by ANOVA. To further test
the recessive allele effect associated with obesity in BFMI
mice, B6 and F1 mice were combined to one group which
was compared with BFMI mice in a second analysis. B6
and F1 mice were both lean and did not differ in fat
deposition.
Metabolites differing significantly between BFMI mice
and the group of B6 and F1 mice, that showed the expected
recessive allele effect, were selected for further analyses.
2.5 Random forest, stepwise selection methods
and candidate metabolite selection
To select candidate metabolites that are linked to genetic
differences between obese and lean mice, we applied two
more methods, the non-parametric random forest (Breiman
2001) and the parametric stepwise selection, which asses-
sed the metabolites as a group. The supervised classifica-
tion method random forest was used to select metabolites
of importance among the 31 highest ranking variables
between the two groups of obese and lean mice. Those 31
metabolites showed most impact on obesity in the internal
permutation test of random forest. Furthermore, selected
metabolites were used for a stepwise selection method on
the logistic regression model. Here, metabolites were used
which showed both significantly different concentrations
between the two compared groups in the logistic regression
and which were also selected using random forest. Those
metabolites were added and dropped from the model one
by one. Akaike’s Information Criterion (AIC) was used to
evaluate the performance of the subsets of metabolites used
in the models. The model with minimal AIC was finally
chosen and metabolites left in this model were potential
independent metabolites that best distinguish lean from
obese mice. Correlated metabolites with less separation
power were dropped. The area under the receiver-operat-
ing-characteristic curves (ROC) was used to evaluate the
models and a likelihood ratio test was used to compare the
models. Calculations were performed under the R statisti-
cal environment (R Core Team 2013).
2.5.1 Network analysis
Metabolite–protein interactions from the Human Metabo-
lome Database (HMDB) (Wishart et al. 2009) and protein–
protein interactions in the Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) (Jensen et al. 2009)
were used to construct a network containing relationships
between metabolites, enzymes and obesity-related genes
(He et al. 2012; Xu et al. 2013). The candidate metabolites
Metabolites in genetically obese mice 463
123
were assigned to the HMDB IDs using the metaP-Server
(Kastenmuller et al. 2011). Their associated enzymes were
derived according to the annotations provided by HMDB.
We chose six obesity candidate genes of the jObes1 region
on chromosome 3 to connect metabolites through the
associated enzymes. In the search for links, we allowed an
intermediate protein through STRING and optimization by
eliminating edges with a STRING score below 0.7 and
undirected paths. The sub-networks were connected by the
shortest path from metabolites to obesity candidate genes.
2.6 Gene expression analysis and sequencing
Gene expression analyses were performed with SMD-fed
male mice of BFMI, B6 and F1 (n = 5–9 per group). Total
RNA was isolated from liver, brain and pancreas using the
nucleic acid and protein purification kit (Machery-Nagel,
Du¨ren, Germany) following the suppliers protocol, and
from reproductive adipose tissue by acid guanidinium
thiocyanate–phenol–chloroform extraction. Genomic DNA
was removed using the Turbo DNA-freeTM Kit (Applied
Biosystems, Foster City CA/USA; Ambion, Austin TX/
USA). 1 lg RNA was reverse-transcribed into cDNA using
AccuScript High Fidelity Transcriptase and oligo-dT
primers according to the manufacturer’s instructions
(Stratagene Europe, Agilent Technologies, Waldbronn,
Germany). Primers for quantitative real-time PCR were
designed using Primer3 software (http://frodo.wi.mit.edu/)
and are given in Table S4. Primers were checked with a
20 ll control PCR contained 50 ng cDNA, 10 lM of each
primer pair and 1 Unit FIRE-Pol DNA Polymerase (Solis
BioDyne, Tartu, Estonia) with a three step PCR standard
program. Fragment length of PCR products were checked
on an agarose gel. Quantitative real-time PCR was per-
formed in a total reaction volume of 10 ll containing
MasterMix Plus for SYBR Assay (Eurogentec, Cologne,
Germany), 10 ng cDNA and 10 lM of the gene specific
primers. Triplicates were measured on ViiaTM 7 Real-Time
PCR System (Applied Biosystems, Darmstadt, Germany).
Gene expression was calculated as relative quantity (RQ)
using the DDCt method (Livak and Schmittgen 2001). As
endogenous controls, Rps25 and b-Actin were chosen and
gene expression was calculated relative to the group of B6
and F1 mice, normalized to a value of 1.
The coding region and 420 bp upstream of the first exon
of Ccna2 were sequenced using cDNA and genomic DNA
of BFMI and B6 mice, respectively. Genomic DNA was
extracted from spleen using phenol and chloroform in a
standard procedure. Sequencing primers were designed
with DNASTAR software (DNASTAR Inc., Madison,
USA) and are given in Table S4. PCR products, amplified
using standard methods, were cut from a 2.0 % agarose gel
and purified using GeneJETTM Gel Extraction Kit
(Fermentas, St. Leon-Rot, Germany). The sequence reac-
tions in both directions were performed with BigDye
Terminator v1.1 Ready Reaction Cycle Sequencing Kit and
an ABI PRISM 310 Genetic Analyser (Applied Biosys-
tems, Darmstadt, Germany) following manufacturers
instruction. Sequences were assembled and analyzed using
the DNASTAR software (DNASTAR Inc., Madison,
USA). The chromosome position of found variations and
reference alleles are based on Ensembl release 67—May
2012, Mouse (NCBIM37). Transcription factor binding
sites were determined with the web tool CONSITE (San-
delin et al. 2004) using human and mouse transcription
factor model matrices and a scoring threshold of 80 %. The
30 UTR of the Ccna2 reference transcript (NM_009828)
was scanned for binding sites of known mouse miRNAs
using the web program PITA (Kertesz et al. 2007) with
standard parameters. Resulting energetic scores estimate
the free binding energy in the seed region of the miRNA–
mRNA duplex and thus the binding strength of the miRNA
to the given 30UTR site. Only scores equal or below -10
were considered as these are likely to be functional in
endogenous miRNA expression levels (Kertesz et al.
2007). Expression data of transcription factors were taken
from the arrays GeneAtlas MOE430 and GNF1M via the
web tool BioGPS (http://biogps.org). MicroRNA expres-
sion data were obtained from the Gene Expression Atlas
(http://www.ebi.ac.uk/gxa/).
3 Results and discussion
3.1 Phenotypic and metabolic characteristics of BFMI,
B6 and F1 mice
Ten weeks old BFMI males on standard maintenance diet
(SMD) had a 4.1 and 4.6 and females a 3.0 and 2.2 times
higher body fat content compared to male and female B6
and F1 mice (p \ 0.001) respectively (Table 1). Feeding a
high-fat diet (HFD), all mice gained additional fat mass.
Due to the recessive jObes1 effect in BFMI mice leading to
obesity (Neuschl et al. 2010) BFMI males showed 3.1- and
2.2-fold and females 3.0- and 2.8-fold higher body fat
content at 10 weeks compared with its B6 and F1 coun-
terparts (p \ 0.001), respectively (Table 1). In addition,
serum concentrations of NEFAs were about 1.4 times
elevated (p \ 0.01) in both sexes of BFMI mice fed an
SMD compared with lean F1 and B6 mice. The differences
were lower in HFD-fed mice with only 1.05 and 1.25 times
increased NEFAs in BFMI males and females, respec-
tively. In accordance to the recessive jObes1 effect, F1 and
B6 males showed no statistical difference in their body fat
content and NEFA serum levels, neither on SMD nor on
HFD (Table 1). In contrast, serum triglyceride levels of
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BFMI mice were about two times as high as in B6 mice on
both diets and both sexes (p \ 0.001), but they showed no
difference to lean F1 animals which had also high triglyc-
eride serum levels.
For the determination of metabolite profiles, metabolites
were first compared between the high-fatness selected
obese BFMI line with lean B6 and BFMI 9 B6 F1 mice in
both sexes and on two diets. Out of 163 targeted metabo-
lites 120 were above the detection limit and passed the
quality control and, therefore, were used in this study; 14
metabolites differed between BFMI and B6 or between
BFMI and F1 mice (Table S2). B6 and F1 mice did not
differ in their metabolite concentrations indicating that the
recessive genetic defect of BFMI mice is mainly respon-
sible for metabolic differences when comparing lean and
BFMI mice. Although sex differences in the metabolic
profile had been reported in humans (Lutz et al. 2006;
Mittelstrass et al. 2011), ANOVA provided evidence that
the sex had no effect in this study. Furthermore, also the
diet had almost no effect, except for diacyl-phosphati-
dylcholine (PC aa) C42:2 which was affected by diet, but
not by line (Table S2). Therefore, the metabolite PC aa
C42:2 as well as the factors sex and diet were not con-
sidered in subsequent analyses. As the focus of this study
was on differences in metabolite concentrations due to
genetic variations between obese BFMI and lean B6 and F1
mice, all BFMI mice of the SMD and HFD groups were
combined to one group of obese mice whereas all B6 and
F1 mice were combined to a group of lean mice. This is
consistent with our expectation of the recessive mode of
action of the obesity effect of the BFMI line leading to
juvenile obesity. Due to the increase of group sizes further
18 metabolites were identified to be different between
obese BFMI and the lean mice in addition to the 13
metabolites that differed between BFMI and either B6 or
F1 mice (Table 2). Overall, BFMI mice had a reduction in
12 serum PC aa, 10 PC ae, 2 lysoPC, 3 acylcarnitines and
increased levels of 3 amino acids and 1 sphingomyeline
when comparing to lean mice. Because these 31 metabo-
lites differed between obese BFMI and lean B6 and F1
mice, we suggest that at least one gene of the genomic
chromosome 3 region, responsible for obesity in BFMI
mice, accounts for the amount of at least one metabolite in
serum of the mice.
Most metabolites that differed between obese and lean
mice belonged to the group of glycerophospholipids that
were all significantly lower in BFMI mice (p \ 0.05). The
glycerophospholipid PC aa C42:1 showed highest signifi-
cance (p = 0.005). The amino acids serine, glycine and
arginine and one hydroxyshingomyelin C22:1 (SM (OH)
C22:1) were higher in BFMI mice.
3.2 Selection of candidate metabolites
Using the 31 metabolites that were found to be significantly
different between lean and obese mice, the random forest
analysis identified the acylcarnitine C14, the amino acid
serine and PC aa C42:1 with high confidential ROC curve
AUC-scores of 0.752, 0.711 and 0.725, respectively, as
those metabolites that were mainly affected by the genetic
background and explained best the genetic differences
between lean and obese mice. Serum serine level was
increased in the obese line compared with lean mice, while
the amount of acylcarnitine C14 and PC aa C42:1 was
reduced in BFMI mice. To find the obesity candidate genes
which might be involved in the regulation of metabolites,
the selected candidate metabolites were connected to
obesity candidate genes of the chromosome 3 jObes1
region by a network analyses. Out of the three significant
metabolites, only PC aa C42:1 showed a functional link to
the obesity candidate genes of the jObes1 locus. In detail,
PC aa C42:1 showed a connection to the genes encoding
Table 1 Phenotypic characteristics of BFMI, B6, and BFMI 9 B6 F1 mice
Trait BFMI B6 F1 ANOVA effects of
Males Females Males Females Males Females Line Sex Diet
SMD HFD SMD HFD SMD HFD SMD HFD SMD HFD SMD HFD
BW 38.3 48.5 27.3 38.6 26.5 25.7 21.5 22.8 28.4 36.2 25 25.4 \0.001 \0.001 \0.001
(g) (1.6) (3.8) (1.5) (6.5) (1.2) (1.4) (0.7) (2.4) (0.8) (2.3) (1) (0.7)
FAT 23.89 31.91 20.79 38.53 5.87 10.35 6.87 12.65 5.14 14.31 9.42 13.63 \0.001 n.s. \0.001
(%) (3.49) (1.51) (4.15) (3.88) (2.119) (4.24) (2.37) (5.71) (2.25) (3.27) (1.22) (4.27)
TG 190.3 151.5 103.1 127.7 102.4 68.9 59.2 69.8 169.5 131.7 148.4 73.2 \0.001 \0.001 0.017
(mg/dl) 41.2 35.6 28 74 34.9 28.8 21 11.7 43.2 27.3 22 16.9
NEFA 1 1 0.8 1 0.7 0.8 0.7 0.7 0.7 0.8 0.8 0.8 0.001 n.s. n.s.
(mmol/l) 0.1 0.1 0.2 0.3 0.1 0.1 0.2 0.1 0.1 0.1 0.2 0.1
Values represent means and standard deviations in parentheses. ANOVA results were considered as statistically significant at p \ 0.05
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Table 2 Metabolites that differ significantly between obese BFMI and the group of lean B6 and F1 mice
Metabolite short name Metabolite biochemical name BFMI B6 ? F1 ANOVA effect of line
PC aa C34:1 Phosphatidylcholine diacyl C34:1 213.02 ± 124.9 313.65 ± 188.48 0.042
PC aa C36:3 Phosphatidylcholine diacyl C36:3 136.34 ± 55.02 181.21 ± 73.58 0.017
PC aa C36:4 Phosphatidylcholine diacyl C36:4 169.75 ± 47.87 202.41 ± 68.46 0.049
PC aa C38:4 Phosphatidylcholine diacyl C38:4 135.81 ± 66.55 181.75 ± 86.61 0.045
PC aa C38:5 Phosphatidylcholine diacyl C38:5 66.1 ± 42.79 98 ± 54.63 0.016
PC aa C40:2 Phosphatidylcholine diacyl C40:2 0.48 ± 0.16 0.59 ± 0.2 0.014
PC aa C40:3 Phosphatidylcholine diacyl C40:3 0.78 ± 0.45 1 ± 0.47 0.033
PC aa C40:4 Phosphatidylcholine diacyl C40:4 3.31 ± 1.71 4.52 ± 2.28 0.028
PC aa C40:5 Phosphatidylcholine diacyl C40:5 14.83 ± 13.34 23.34 ± 16.81 0.05
PC aa C42:1 Phosphatidylcholine diacyl C42:1 0.15 ± 0.04 0.17 ± 0.04 0.005
PC aa C42:5 Phosphatidylcholine diacyl C42:5 0.34 ± 0.12 0.4 ± 0.1 0.02
PC aa C42:6 Phosphatidylcholine diacyl C42:6 0.83 ± 0.23 1 ± 0.3 0.02
PC ae C36:0 Phosphatidylcholine acyl-alkyl C36:0 0.92 ± 0.55 1.18 ± 0.59 0.048
PC ae C38:1 Phosphatidylcholine acyl-alkyl C38:1 2.35 ± 1.87 3.62 ± 2.49 0.05
PC ae C38:3 Phosphatidylcholine acyl-alkyl C38:3 3.51 ± 2.18 4.86 ± 2.7 0.049
PC ae C40:4 Phosphatidylcholine acyl-alkyl C40:4 3.19 ± 1.36 4 ± 1.57 0.036
PC ae C40:5 Phosphatidylcholine acyl-alkyl C40:5 2.2 ± 1.33 2.94 ± 1.52 0.036
PC ae C42:0 Phosphatidylcholine acyl-alkyl C42:0 1.03 ± 0.3 1.29 ± 0.45 0.017
PC ae C42:1 Phosphatidylcholine acyl-alkyl C42:1 0.72 ± 0.18 0.92 ± 0.35 0.008
PC ae C42:2 Phosphatidylcholine acyl-alkyl C42:2 0.83 ± 0.53 1.17 ± 0.7 0.046
PC ae C44:3 Phosphatidylcholine acyl-alkyl C44:3 0.13 ± 0.03 0.16 ± 0.04 0.006
PC ae C44:4 Phosphatidylcholine acyl-alkyl C44:4 0.16 ± 0.07 0.18 ± 0.05 0.015
lysoPC a C16:1 lysoPhosphatidylcholine acyl C16:1 10.5 ± 3.68 12.69 ± 3.92 0.049
lysoPC a C18:1 lysoPhosphatidylcholine acyl C18:1 90.23 ± 58.24 121.75 ± 62.9 0.048
Ser Serine 108.43 ± 47.37 81.63 ± 31.65 0.009
Gly Glycine 232.3 ± 59.7 194.3 ± 59.9 0.025
Arg Arginine 152.8 ± 38.5 132.2 ± 39.2 0.031
C14 Tetradecanoylcarnitine 0.08 ± 0.02 0.1 ± 0.05 0.003
C14:1 Tetradecanoylcarnitine 0.12 ± 0.03 0.14 ± 0.03 0.003
C18:1 Octadecanoylcarnitine 0.15 ± 0.05 0.21 ± 0.09 0.002
SM (OH) C22:1 Hydroxysphingomyelin C22:1 4.19 ± 2.75 3.16 ± 1.56 0.04
Values are shown as means ± standard deviations. Differences were considered statistically significant at p \ 0.05
Fig. 1 Effects of the metabolite PC aa C42:1. a Serum concentration
of the metabolite PC aa C42:1 in BFMI and the combined group of B6
and F1 mice are given in mean ± standard error. b Network
composed of PC aa C42:1, the interacting enzymes CHKA and
PLA2G1B and the underlying genes Ccna2 and Trpc3. CHKA choline
kinase a; PLA2G1B phospholipase A2 group 1B; Ccna2 cyclin A2
and Trpc3 transient receptor potential cation channel subfamily C,
member 3
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for cyclin A2 (Ccna2) and the transient receptor potential
cation channel subfamily C, member 3 (Trpc3) (Fig. 1) of
the jObes1 locus. The interaction is given via the enzymes
choline kinase alpha (CHKA) and PLA2G1B, respectively.
3.3 Obesity candidate gene characterization
To characterize the potential impact of the obesity candidate
genes on the lower PC aa C42:1 serum metabolite level in
BFMI mice, gene expression analyses of the network genes
Ccna2, Chka, Pla2g1b and Trpc3 were performed. Although
weakly expressed, the obesity candidate gene Ccna2 was
2.3-times up-regulated in BFMI compared with B6 and F1
mice in the reproductive adipose tissue (Fig. 2). However,
the adipogenic mRNA amount of Chka encoding the inter-
acting enzyme did not differ between BFMI and B6 mice. In
the liver, only Chka was found to be expressed, whereas
Ccna2 mRNA was not detected. The hepatic Chka expres-
sion did not differ between groups. Pla2g1b and Trpc3 were
expressed neither in the reproductive adipose tissue nor in
the liver, but could be detected in the pancreatic and brain
tissue, respectively. However, as only Ccna2 and Chka were
expressed in adipose tissue which is one of the main sites for
metabolite metabolism, only Ccna2 seems to be the obesity
gene which contributes to reduced serum phosphatidylcho-
line concentrations in BFMI mice.
To further characterize the different expressions of
Ccna2 between BFMI and B6 mice, comparative
sequencing of the promoter and coding regions was per-
formed. Overall, 29 mutations were found when comparing
the sequences, thereof 24 SNPs and five InDels. One
deletion in the promoter region, two SNPs in the 50
untranslated region (UTR), one coding SNP in exon 1, one
SNP and three InDels in the 30UTR were unique to the
BFMI line compared with the reference sequence of B6
and the SNP database (Welcome Trust Sanger Institute,
http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/
snps.pl) (Table 3). The two SNPs in the protein coding
region were synonymous. The in silico analysis of the
detected variants revealed seven SNPs and one InDel in the
sequenced 420 bp promoter region as well as two SNPs in
the 50-UTR/exon1 region that are predicted to gain or lose
transcription factor binding sites or modify the binding
capacity in BFMI mice compared with B6 (Table 3).
Furthermore, seven SNPs and two insertions create new
micro RNA recognition sites and one SNP, one deletion
and the two insertions lead to the loss of micro RNA
binding sites in the 30 UTR (Table 3). Since some tran-
scription factors and micro RNAs occur in the adipose
tissue (Table S3), both variations in the promoter and the 30
UTR could affect the amount of Ccna2 transcripts in the
adipose tissue.
Fig. 2 Gene expression of
candidate genes of the network
analysis in obese BFMI and lean
B6 and F1 mice. a PCR
products of Rps25, Chka,
Ccna2, Trpc3 and Pla2g1b in
reproductive adipose, liver,
brain and pancreas tissue of
BFMI mice. b Relative mRNA
expression level of Chka in
reproductive adipose tissue
(n = 5–9). c Relative mRNA
expression level of Ccna2 in
reproductive adipose tissue
(n = 5–9). Bar graphs are given
as mean values plus standard
deviation. Bar graphs with
different letters are significantly
different at p \ 0.05
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3.4 Metabolite pathways and the biological context
Generally, PCs account for 50 % of eukaryotic membrane
phospholipids (van Meer et al. 2008) and are essential for
coating lipid droplet surfaces (Krahmer et al. 2011). Fur-
ther, PCs stimulate adipocyte differentiation and increase
triglyceride levels of 3T3-L1 and preadipocytes (Zhang
et al. 2009). Apart from structural functions of PCs in
membranes, they serve as substrates for the synthesis of
diacylglycerides and subsequent triglycerides and free fatty
acids in the liver. In the BFMI line lowered levels of
several serum PCs and higher triglyceride and free fatty
acid synthesis compared with lean mice also indicate the
important role of PCs in fat metabolism. Therefore, PC
emerged as most interesting metabolite in connection with
obesity, but a direct link between the specified PC aa C42:1
and obesity has not been found in the literature now.
Within the metabolite–protein network the interaction of
PC aa 42:1 with the obesity candidate genes Ccna2 and
Trpc3 was given via the enzymes CHKA and PLA2G1B,
respectively. However, only Ccna2 and Chka were
expressed in adipose tissue which is one of the main sites
for metabolite metabolism. Thus, Ccna2 seemed to be the
obesity gene which contributed to lower serum PC con-
centrations in BFMI mice. The functional role of the
pathway including the enzyme CHKA and PC aa C42:1
became evident as CHKA catalyzes the initial phosphory-
lation step of choline within PC synthesis via the cytidine
diphosphocholine pathway (Kent 2005). CCNA2 in turn is
a cyclin family member, which is well known to regulate
mitotic cell division by associating to cyclin dependent
protein kinases (Johnson and Walker 1999). A gene dis-
ruption resulted in embryonic lethality (Murphy et al.
1997) demonstrating its essential regulatory role. An ele-
vated expression of Ccna2 in the reproductive adipose
tissue of BFMI mice likely leads to increased mitotic
activity of adipocytes. While there was no indication for an
increased adipocyte number in BFMI mice (Wagener et al.
2010), the size of adipocytes was increased to compensate
the higher lipid storage and an ongoing turnover of adi-
pocytes can be assumed. This assumption is in line with
human studies reporting on more newly generated adipo-
cytes in obese adults than in lean adults, despite constant
adipocyte numbers (Spalding et al. 2008).
An increased adipocyte turnover in BFMI mice required
PCs as an essential membrane component. PC aa C42:1
seemed to be one of the major membrane PCs that may be
regulated by Ccna2 in the obese line. The demand for high
PC amounts for membrane production was jointly
responsible for lower available serum PCs in BFMI mice,
in particular as cytidinediphosphocholine pathway seemed
to be normal which was indicated by unchanged Chka
expression between obese and lean mice.
Since no hepatic Ccna2 expression could be detected in
BFMI and B6 mice, we suggest a tissue-specific expression
pattern which goes along with the specific increase of
adipocyte production in obese subjects. The genetic mod-
ifications in the promoter region of Ccna2 cause new or
lost putative transcription factor binding sites in the BFMI
line and might be responsible for differential regulation of
expression between lean and obese mice. Furthermore, an
increase in mRNA stability due to the comprehensive
variations in the 30 untranslated region cannot be excluded
and could lead to increased translation ending in a higher
CCNA2 protein availability within the adipose tissue of
BFMI mice. Since several binding sites of transcription
factors and miRNAs that occur in adipose tissues are
modified, the transcriptional or translational regulation of
the alternative Ccna2 haplotype in BFMI is likely.
The second pathway branch linked Trpc3 with PC aa
C42:1 via PLA2G1B. Trpc3 as a member of the transient
receptor potential superfamily encodes for cation channels.
Cations such as calcium are required for PLA2G1B action
which is secreted by the pancreas into the intestinal lumen
to digest dietary fatty acids (Carey et al. 1983). Since no
gene expression of Trpc3 was observed either in the
reproductive adipose tissue or in the liver between BFMI
and B6 mice, we assumed that this pathway is not involved
in the regulation of PC aa C42:1.
4 Concluding remarks
In the present study, serum metabolites of genetically obese
BFMI and lean mice were compared. Secondly, signifi-
cantly different metabolites were linked with underlying
obesity candidate genes revealing PC aa C42:1 as being
influenced by the genetic background for obesity in BFMI
mice. Ccna2 and Trpc3 were selected as candidate genes
affecting PC aa C42:1 serum levels via the enzymes CHKA
and PLA2G1B. To uncover the biological context of the
specified PC aa C42:1 and respective genes, expression
analysis and comparative sequencing were performed in
BFMI and lean mice. Unique mutations in the Ccna2
promoter of obese mice were identified which are located
either in transcription factor or micro RNA binding sites.
These genetic modifications are postulated to affect Ccna2
gene expression in adipose tissue likely leading to higher
mitotic activity of adipocytes. In conclusion, adipose tissue
growth and remodeling are increased in obese mice and
cause a higher demand of specific PCs.
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